Achieve TMS Central is excited to offer Deep TMS for the treatment for Depression and Obsessive-Compulsive Disorder in the Mason City area.
Achieve TMS Central’s mission is to help those suffering from Major Depressive Disorder and OCD with Deep TMS Therapy. This is why we’ve opened Achieve TMS Central – Mason City as a convenient location with easy parking. Our center proudly offers the revolutionary Deep TMS therapy (transcranial magnetic stimulation)—an FDA-approved and highly effective form of depression treatment. We started in Massachusetts, expanded to Connecticut, and now we are going across the nation starting in Iowa!
Short bursts of magnetic pulses are directed to the limbic system or mood center of the brain. Patients typically start to see positive results in two or three weeks. There’s no need for anesthesia, and there are none of the systemic side effects associated with medications.
TMS therapy in Mason City is simple. Just come to our Mason City center for a 20-minute session each day and then drive back to work or home. That’s it. TMS therapy could be the hope you’re looking for. You won’t know unless you try.
Take the next step. Regain joy.
Give us a call at (641) 435-6948 for a free wellness consultation or email us at firstname.lastname@example.org to learn more.
Insurance accepted for Depression Treatment, specifically TMS therapy, has more than doubled in the last few years, a sign that insurance companies must see cost savings in a treatment method for major depressive disorder (MDD) that works more efficiently than the traditional regimen alone. Patients who continually suffer from the debilitating effects of medication-resistant depression may acquire other health conditions as a result, such as a substance abuse disorder or unhealthy weight gain, to name a few. The fact that more and more insurance companies are providing coverage for TMS indicates a cost benefit to the insurer, thus the broadening of benefits.
*Official FDA Approval is currently for depression and OCD but several other uses are awaiting approval.